Skip Navigation


Schizophrenia Bulletin Advance Access originally published online on June 19, 2007
Schizophrenia Bulletin 2007 33(5):1153; doi:10.1093/schbul/sbm073
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
33/5/1153    most recent
sbm073v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Laughren, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laughren, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press 2007.

Wayne Fenton: Impact on Food and Drug Administration

Thomas Laughren1,2
2 Division of Psychiatry Products, Food and Drug Administration

The first 10% of the full text of this article appears below.

I had known about Wayne Fenton for a number of years before I had an opportunity to meet him. He had written several articles that I found quite interesting, and my wife, who is a psychiatric nurse, had met him and spoke very highly of him. He had been to her unit to recruit patients for studies, and she had some other contact with him involving patients he treated. She considered him . . . [Full Text of this Article]

1 To whom correspondence should be addressed; tel: 301-796-2260, fax: 301-796-9838, e-mail: thomas.laughren@fda.hhs.gov.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?